The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs.

Bendicksen, Liam; Kesselheim, Aaron S; Rome, Benjamin N

Bendicksen, Liam; Kesselheim, Aaron S; Rome, Benjamin N.

Bendicksen L; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Kesselheim AS; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Rome BN; Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Electronic address: brome@bwh.harvard.edu.

Chest ; 162(2): 433-435, 2022 08.

Artículo en Inglés | MEDLINE | ID: covidwho-2031192

Asunto(s)

Aprobación de Drogas; Vasopresinas; Industria Farmacéutica; Humanos; Estados Unidos; United States Food and Drug Administration

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Vasopresinas / Aprobación de Drogas Límite: Humanos País/Región como asunto: America del Norte Idioma: Inglés Revista: Chest Año: 2022 Tipo del documento: Artículo País de afiliación: J.chest.2022.02.048

Similares

MEDLINE

LILACS

LIS

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google